Option Care Health (NASDAQ:OPCH) Issues FY 2024 Earnings Guidance

Option Care Health (NASDAQ:OPCH) updated its FY 2024 earnings guidance on Monday. The company provided earnings per share guidance of 1.550-1.590 for the period, compared to the consensus earnings per share estimate of 1.210. The company issued revenue guidance of $5.0 billion-$5.0 billion, compared to the consensus revenue estimate of $4.9 billion. Option Care Health also updated its FY 2025 guidance to 1.590-1.690 EPS.

Option Care Health Trading Up 3.6 %

Shares of OPCH opened at $28.72 on Wednesday. The company has a debt-to-equity ratio of 0.77, a current ratio of 1.73 and a quick ratio of 1.32. Option Care Health has a 1-year low of $21.39 and a 1-year high of $34.63. The stock has a market cap of $4.89 billion, a price-to-earnings ratio of 24.13, a price-to-earnings-growth ratio of 2.43 and a beta of 1.31. The firm has a 50 day simple moving average of $23.33 and a 200-day simple moving average of $27.70.

Wall Street Analysts Forecast Growth

A number of equities analysts have recently weighed in on the company. Bank of America raised Option Care Health from a “neutral” rating to a “buy” rating and boosted their price target for the stock from $26.00 to $33.00 in a report on Monday. The Goldman Sachs Group downgraded shares of Option Care Health from a “buy” rating to a “neutral” rating and cut their target price for the company from $38.00 to $27.00 in a research note on Monday, November 4th. UBS Group assumed coverage on shares of Option Care Health in a research note on Thursday, December 5th. They set a “neutral” rating and a $26.00 price target on the stock. JMP Securities reissued a “market outperform” rating and issued a $30.00 price objective (down previously from $31.00) on shares of Option Care Health in a research report on Friday, January 10th. Finally, Jefferies Financial Group downgraded shares of Option Care Health from a “buy” rating to a “hold” rating and reduced their price objective for the company from $38.00 to $26.00 in a research note on Thursday, October 31st. Three equities research analysts have rated the stock with a hold rating and four have issued a buy rating to the company. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $29.86.

Insider Activity

In related news, Director Harry M. Jansen Kraemer, Jr. purchased 43,000 shares of the firm’s stock in a transaction on Friday, November 8th. The shares were bought at an average price of $22.54 per share, for a total transaction of $969,220.00. Following the acquisition, the director now directly owns 326,334 shares in the company, valued at $7,355,568.36. This trade represents a 15.18 % increase in their ownership of the stock. The acquisition was disclosed in a filing with the SEC, which is available at this link. Corporate insiders own 0.64% of the company’s stock.

About Option Care Health

Option Care Health, Inc offers home and alternate site infusion services in the United States. The company provides anti-infective therapies; home infusion services to treat heart failures; home parenteral nutrition and enteral nutrition support services for numerous acute and chronic conditions, such as stroke, cancer, and gastrointestinal diseases; immunoglobulin infusion therapies for the treatment of immune deficiencies; and treatments for chronic inflammatory disorders, including crohn’s disease, plaque psoriasis, psoriatic arthritis, rheumatoid arthritis, ulcerative colitis, and other chronic inflammatory disorders.